

FORM 7

MONTHLY PROGRESS REPORT

Name of Listed Issuer: **GLOBAL HEMP GROUP INC.** (the "Issuer").

Trading Symbol: **GHG**

Number of Outstanding Listed Securities: **355,693,392**

Date: **February 7, 2023**

1. Provide a general overview and discussion of the development of the Issuer's business and operations over the previous month. Where the Issuer was inactive disclose this fact.

Revitalize Earth Transaction

On January 3, 2023 the Company announced that it would not be proceeding with the contemplated transaction with Revitalize Earth.

Execution of Exclusive Licensing Agreement for Intellectual Property of [Apollon Formularies plc](#)

On [January 11, 2023 the company announced](#) that it had executed a binding Letter of Intent with Apollon Formularies covering exclusive North American licensing of certain Apollon Patents and the Intellectual Property (the "IP").

Apollon is a UK-based international pharmaceutical company developing cancer treatments from natural biologics, including medical cannabis, functional mushrooms, psychedelic mushrooms and most importantly combinations of these compounds, and utilizing an artificial intelligence-based drug discovery platform. These formulations have demonstrated significant success in independent, third-party pre-clinical testing (see Apollon's July 19, 2021 news release "[Apollon Formulations Kill Prostate Cancer Cells](#)" for further information).

Under the terms of the binding LOI dated January 9, 2023, GHG will acquire the exclusive perpetual license for North America (specifically, the United States, Canada and Mexico) for, but not limited to, four key patents as described below including any continuations, divisionals, and continuations-in-part, along with any and all associated preclinical and clinical data relating to the patents and proprietary technology (the "IP").

For further information on the Exclusive License being acquired from Apollon Formularies, Plc <https://www.globalhempgroup.com/apollon-patents-ip>

Under the terms of the binding LOI, the Company has also been granted a 60-day option to conduct due diligence, following which GHG may exercise its option to acquire the entirety of Apollon's global assets.

Terms of the Option to Acquire the Entire Assets of Apollon

The LOI provides for a due diligence period, currently set at 60 days, during which GHG and Apollon may gather further information about each other's business and finances. If both parties are satisfied with the results of the due diligence, GHG will have the exclusive option to acquire all the assets of Apollon other than cash, cash equivalents, and receivables, for a payment of 771,191,266 GHG common shares at a deemed price of \$0.015 per GHG common share, for total consideration of C\$11,567,869. All securities which may be issued relating to this portion of the transaction will be subject to a minimum of four-month plus a day hold period from the date of issuance and any other customary delayed release escrow provisions customary for these type of transactions in accordance with applicable securities laws. In the event that GHG exercises this option to acquire the assets of Apollon, the Company will ask shareholders to consider a share consolidation on a basis of 5 old for 1 new share, and the proposed transaction would be considered a fundamental change for the Company, per CSE Policy 8. GHG will pay a finder's fee to Twilight Capital Inc. or such other affiliate, designee, or associate, representing five percent (5%) of the value of the entire Transaction between GHG and Apollon (the "Finder's Fee"). The Finder's Fee relating to the Asset Acquisition portion of the transaction, if concluded, will be payable either in cash, GHG Shares or a combination of both.

Apollon Formularies Plc Assets that will be Acquired on Exercise of Option:

- 8 patent applications (4 PCT; 4 Jamaica).
- BIOENSIS Preclinical data.
- The right to acquire 49% Equity in Apollon Formularies Jamaica, Ltd. ("Apollon Jamaica") with approval of the Jamaican Cannabis Licensing Authority ("CLA").
- 95% net profits from all operations in Apollon Jamaica, Ltd.

Apollon Formularies Jamaica, Ltd. Assets

- CLA Medical Cannabis Licenses (Processing, Retail Therapeutic, Research & Development) and all equipment required to perform under the licenses. Licenses allow import and export of products globally where legally allowed.
- The Medical Cannabis R&D license allows the Company to perform human clinical trials with approval of the Jamaican Ministry of Health.
- International Cancer and Chronic Pain Institute (fully medically equipped and furnished).
- Control of CITIVA Jamaica (University location and Affiliation). Includes CLA Cultivation License which allows import and export of products globally where legally allowed. Fully equipped and furnished. GMP approval pending final inspection.
- Medical cannabis inventory: approximate retail value US\$350,000 (unaudited figures).
- A signed processing agreement for a hemp farming group in Jamaica. Apollon will process, for a fee, the hemp cultivated into CBD oil for global export. It is expected that the farming group will have multiple crops per year available for processing.

- Contract to run clinical trials at the Apollon’s facility for a U.S. biotherapeutics company on a cost-plus basis.
- Therapeutic Dispensary (fully equipped and furnished).
- Processing Laboratory (fully equipped and furnished).
- Research and Development Facility (fully equipped and furnished).

Also as part of the binding LOI, Dr. Stephen Barnhill, Chairman & CEO of Apollon and creator of the IP will join GHG as its Special Medical Advisor to assist the Company in entering North American markets to sublicense the IP acquired under the LOI.



Dr. Barnhill is a Medical Doctor specializing in Cannabinoid and Mycomedicinal Therapeutics, Drug Discovery and Artificial Intelligence, and has completed a Clinical Fellowship in Laboratory Medicine (Clinical Pathology) at the Medical University of South Carolina (MUSC).

Previously, Dr. Barnhill was Founder, Chairman and CEO of both private and public companies, including Founder, Chairman, and CEO of BCL laboratories, LLC with operations in southeastern US, which was acquired by Corning–MetPath now Quest Diagnostics, the largest clinical laboratory in the world. For further information on Dr. Barnhill, visit <https://www.globalhempgroup.com/dr-stephen-barnhill> .

On January 23, 2023 the Company announced that it had had executed the exclusive licensing agreement covering the licensing of the right to Apollon’s Patent Applications and the Technology as described above.

Licensing Fee - During the Term of this License Agreement GHG shall pay a quarterly licensing fee to Apollon (“Licensing Fee”), the payment of which shall be triggered when revenues are first generated from sublicensing activities. Payment of the Licensing Fee shall commence with the subsequent quarter. The Licensing Fee shall equal 10% of gross sublicensing fees received by GHG, and the Parties agree to reconsider the Licensing Fee from time to time, and if circumstances warrant, the Parties agree to negotiate in good faith to determine a reasonable revised License Fee.

Global Hemp Group will now look to begin an IP sub-licensing program to legally licensed manufacturers, distributors, and retailers in any and all locations where legally permitted in the United States, Canada, and Mexico. Until now, Apollon has been precluded from entering the North American market to license and sub-license its IP due to jurisdictional constraints placed on Apollon being an Aquis Exchange listed UK company. Dr. Stephen Barnhill, the Company’s Special Medical Advisor and creator of Apollon’s IP will assist GHG in entering these markets. For further information on Dr. Barnhill, visit <https://www.globalhempgroup.com/dr-stephen-barnhill> .

GREEN COMMUNITY IN HAYDEN COLORADO

To date, the Company has experienced significant delays in its payment obligations under the existing Definitive Agreement executed with Western Sierra Resources Corporation (WSRC) and Prescient Solutions Group LLC. During the course of 2022 the Company has worked with WSRC to restructure the Definitive Agreement to clarify and simplify the relationship of the parties, with the execution of either a revised Definitive Agreement or Joint Venture agreement. During the last week of January GHG had discussions with WSRC regarding potential direct funding partners for the project under a new Joint Venture scenario. Unfortunately, these discussions did not result in a new joint venture agreement being executed for the Hayden project.

Research & Development Division - Expansion of Activities

The R&D Division in Querétaro Mexico continues to be an important component of Company's business model. The R&D team is currently focused on development of patented technology ("IP") that can be widely marketed.

The group is completing work on two initial patents that it expects to file in the first quarter of the year. The first, a novel building material utilizing hemp fibre that has been chemically modified to increase its mechanical performance and then combined with rice husks, an important agricultural by-product found worldwide, creating a product that could be used as a replacement for Medium-Density Fibreboard (MDF) in construction. As rice husks are not biodegradable, this is an ideal method for utilizing the waste from the rice industry. The second patent is an environmentally friendly procedure to extract CDB and other cannabinoids from hemp utilizing enzymes from natural products. The process has proven to be economical, while leaving no residual chemicals or solvents.

The R&D group is also actively exploring additional academic and economic partnerships to expand its research endeavours relating to hemp and hemp-based products.

 [Subscribe to our YouTube channel](#)

 [Follow us on LinkedIn](#)

 [Follow us on Instagram](#) @hemp_global

 [Like us on Facebook](#) @globalhempgrp

 [Follow us on Twitter](#) @Hemp_Global

2. Provide a general overview and discussion of the activities of management.
In addition to the above, Management continues to work to complete the year end financial audit.
3. Describe and provide details of any new products or services developed or offered. For resource companies, provide details of new drilling, exploration or production programs and

acquisitions of any new properties and attach any mineral or oil and gas or other reports required under Ontario securities law.

None

4. Describe and provide details of any products or services that were discontinued. For resource companies, provide details of any drilling, exploration or production programs that have been amended or abandoned.

None

5. Describe any new business relationships entered into between the Issuer, the Issuer's affiliates or third parties including contracts to supply products or services, joint venture agreements and licensing agreements etc. State whether the relationship is with a Related Person of the Issuer and provide details of the relationship.

The Company entered into a contract with Global One Media to provide social media management & advertising services, along with social media distribution of news releases, and monthly video interviews and podcasts. This is a 6 month contract for \$3,000 per month. Global One is an arms-length relationship.

Licensing agreement with Apollon Formularies plc – see #1 above.

6. Describe the expiry or termination of any contracts or agreements between the Issuer, the Issuer's affiliates or third parties or cancellation of any financing arrangements that have been previously announced.

None

7. Describe any acquisitions by the Issuer or dispositions of the Issuer's assets that occurred during the preceding month. Provide details of the nature of the assets acquired or disposed of and provide details of the consideration paid or payable together with a schedule of payments if applicable, and of any valuation. State how the consideration was determined and whether the acquisition was from or the disposition was to a Related Person of the Issuer and provide details of the relationship.

None

8. Describe the acquisition of new customers or loss of customers.

None

9. Describe any new developments or effects on intangible products such as brand names, circulation lists, copyrights, franchises, licenses, patents, software, subscription lists and trade-marks.

None

10. Report on any employee hirings, terminations or lay-offs with details of anticipated length of lay-offs. **None**

11. Report on any labour disputes and resolutions of those disputes if applicable.

None

12. Describe and provide details of legal proceedings to which the Issuer became a party, including the name of the court or agency, the date instituted, the principal parties to the proceedings, the nature of the claim, the amount claimed, if any, if the proceedings are being contested, and the present status of the proceedings.

None

13. Provide details of any indebtedness incurred or repaid by the Issuer together with the terms of such indebtedness. **The Company received a loan of US\$100,000 from an arms-length source. This loan will bear interest at a rate of 7% per annum, and is due and payable on or before July 31, 2023, unless extended by mutual agreement.**
14. Provide details of any securities issued/returned to treasury, and options or warrants granted.

Security	Number Issued	Details of Issuance	Use of Proceeds ⁽¹⁾
common shares	10,000,000	Per the binding Letter of Intent with Apollon Formularies and announced Jan 11/23 relating to the acquisition of the exclusive North American rights to various Apollon patents and IP	N/A
common shares	10,000,000	Compensation for Dr. Stephen Barnhill's services as GHG's Special Medical Advisor	N/A

⁽¹⁾ State aggregate proceeds and intended allocation of proceeds.

15. Provide details of any loans to or by Related Persons.
None
16. Provide details of any changes in directors, officers or committee members.
None
17. Discuss any trends which are likely to impact the Issuer including trends in the Issuer's market(s) or political/regulatory trends.
None

Certificate of Compliance

The undersigned hereby certifies that:

1. The undersigned is a director and/or senior officer of the Issuer and has been duly authorized by a resolution of the board of directors of the Issuer to sign this Certificate of Compliance.
2. As of the date hereof there where is no material information concerning the Issuer which has not been publicly disclosed.
3. The undersigned hereby certifies to CNSX that the Issuer is in compliance with the requirements of applicable securities legislation (as such term is defined in National Instrument 14-101) and all CNSX Requirements (as defined in CNSX Policy 1).
4. All of the information in this Form 7 Monthly Progress Report is true.

Dated: February 7, 2022 .

Curt Huber

Name of Director or Senior Officer

"Curt Huber"

Signature

President & CEO

Official Capacity

Issuer Details Name of Issuer Global Hemp Group Inc.		For Month End January 2023	Date of Report YY/MM/DD 2023/02/07
Issuer Address #106 – 1169 Mt. Seymour Road			
City/Province/Postal Code North Vancouver, BC V7H 2Y4	Issuer Fax No. N/A	Issuer Telephone No. 778-726-2900	
Contact Name Curt Huber	Contact Position President & CEO	Contact Telephone No. 778-726-2900	
Contact Email Address info@globalhempgroup.com	Web Site Address www.globalhempgroup.com		